Table 2.
Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) Study Patient Characteristics and Neurocognitive Classification
| Patient Characteristics | NAMACO Study (N = 909) |
|---|---|
| Age (years), median (IQR) | 53 (49–59) |
| Sex, male n (%) | 724 (79.7) |
| Ethnicity n (%) | |
| Caucasian | 834 (91.8) |
| Other (Black, Hispanic, Asian) | 75 (8.2) |
| Education (years), median (IQR) | 13 (12–14) |
| HIV Transmission Risk Group n (%) | |
| Men having sex with men | 466 (51.3) |
| Heterosexual contact | 302 (33.2) |
| Intravenous drug use | 73 (8.0) |
| Othera | 68 (7.5) |
| Neurocognitive impairment (NCI), n (%) | |
| Normal neurocognitive assessment | 547 (60.2) |
| Asymptomatic neurocognitive impairment | 230 (25.3) |
| Mild neurocognitive disorder | 7 (0.8) |
| HIV-associated dementia | 6 (0.6) |
| Other—non-HIV-associated NCIb | 119 (13.1) |
Abbreviations: ART, antiretroviral therapy; CNS, central nervous system; HIV, human immunodeficiency virus; IQR, interquartile range.
aTransfusion, perinatal transmission, uncertain cause.
bPresence of factors other than HIV infection potentially contributing to neurocognitive impairment: CNS opportunistic infection, ART toxicity, psychiatric disorder, substance use, neurodegenerative disorder, and ischaemic stroke.